GLP-1 Agonists & Heart Failure:
What the STEP-HFpEF Trial Actually Proved

1. The Heart Failure Puzzle: Why HFpEF Has Been So Hard to Treat

Heart failure is not one disease — it is a clinical syndrome divided primarily by how well the heart pumps. Ejection fraction (EF), the percentage of blood the left ventricle pumps out with each beat, is the dividing line.

Heart failure with reduced ejection fraction (HFrEF) — also called systolic heart failure — occurs when EF falls below 40%. The heart muscle is weak. Landmark drug classes (ACE inhibitors, beta-blockers, SGLT2 inhibitors, sacubitril/valsartan) all reduce mortality in HFrEF. These therapies have transformed HFrEF outcomes over three decades.

Heart failure with preserved ejection fraction (HFpEF) is the opposite problem: the heart pumps normally (EF ≥50%) but is pathologically stiff. It cannot relax and fill properly during diastole. This diastolic dysfunction causes the same symptoms as HFrEF — breathlessness, fatigue, exercise intolerance — but the underlying mechanism is fundamentally different. For years, cardiologists had almost nothing to offer HFpEF patients. Drug after drug that worked in HFrEF failed to reduce mortality in HFpEF.

HFpEF now accounts for more than 50% of all heart failure cases in developed countries and is the dominant form in women and older adults. The obesity epidemic has made it far more common.

2. How Obesity Drives HFpEF — The Mechanistic Cascade

To understand why GLP-1 agonists work in HFpEF, you have to understand how obesity creates the disease in the first place. The connection is deeper and more direct than most patients realize.

Pericardial Fat Compression

Excess visceral fat deposits directly around and within the heart — in the pericardial sac and within the myocardium itself as epicardial fat. This fat mass exerts direct mechanical pressure on the cardiac chambers, raising filling pressures and reducing diastolic compliance. Imaging studies consistently show that pericardial fat volume is independently associated with HFpEF severity, even after adjusting for BMI.

Chronic Systemic Inflammation

Adipose tissue — especially visceral fat — is not metabolically inert. It secretes pro-inflammatory cytokines including TNF-alpha, IL-6, and leptin while reducing adiponectin. This chronic low-grade inflammatory state triggers myocardial fibrosis: the deposition of collagen within heart muscle that makes it stiffer and impairs relaxation. Inflammation also disrupts nitric oxide signaling in cardiomyocytes, further impairing their ability to relax during diastole.

Increased Preload and Blood Volume

Obesity increases total blood volume, which raises venous return to the right heart. This increased preload pushes filling pressures higher in the left atrium and pulmonary circulation, causing the breathlessness and fluid congestion characteristic of HFpEF. Exercise dramatically worsens this because cardiac output demands rise without a compliant ventricle to accommodate them.

Insulin Resistance and Hypertrophy

Insulin resistance — near-universal in obese individuals — promotes hypertrophy of cardiomyocytes and impairs their energy metabolism. The obese heart increasingly relies on free fatty acids rather than glucose for fuel, a metabolically inefficient shift that contributes to the diastolic dysfunction seen on echocardiography.

3. The STEP-HFpEF Trial: Design, Results, and What They Mean

The STEP-HFpEF trial (Semaglutide Treatment Effect in People with Obesity and HFpEF) was a randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine in August 2023. It enrolled 529 patients and was designed to test whether semaglutide 2.4 mg once weekly — the weight-loss dose used in the STEP obesity trials — could improve heart failure outcomes in obese HFpEF patients.

Patient Population

Eligible patients had confirmed HFpEF (ejection fraction ≥45%), BMI ≥30 kg/m², NYHA functional class II-IV symptoms, and elevated NT-proBNP (>300 pg/mL, or >900 pg/mL if in atrial fibrillation). Crucially, patients with type 2 diabetes were excluded — the trial was specifically designed to test effects in non-diabetic obesity.

Dual Primary Endpoints

The trial used two co-primary endpoints — an approach that reflects how difficult it is to measure HFpEF improvement. Both had to show significant benefit:

• Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS): A validated patient-reported measure of heart failure symptoms and physical limitations, scored 0–100. Higher is better.
• 6-Minute Walk Distance (6MWD): How far a patient can walk in 6 minutes — a well-validated measure of functional exercise capacity.

Results at 52 Weeks

The results were unambiguous for both endpoints:

• KCCQ-CSS: Improved by 16.6 points in the semaglutide group versus 8.7 points with placebo. A difference of 7.8 points — clinically meaningful and statistically significant (p<0.001). A 5-point change in KCCQ-CSS is generally considered the minimum clinically important difference.
• 6MWD: Semaglutide patients walked 21.5 meters more than placebo patients at 52 weeks (p<0.001). For HFpEF patients who struggle to walk to their mailbox, this is functionally significant.

Secondary Endpoints

The secondary findings reinforced the primary results:

• Mean body weight reduction: −13.3% with semaglutide vs −2.6% with placebo
• C-reactive protein (CRP, an inflammation marker): significantly reduced with semaglutide
• NT-proBNP levels: decreased more with semaglutide than placebo
• Waist circumference: significantly reduced, consistent with visceral fat loss

A parallel trial, STEP-HFpEF DM, enrolled patients with type 2 diabetes and showed similarly strong results, effectively extending the finding across the glucose spectrum of the obese HFpEF phenotype.

4. The Mechanism: How Semaglutide Helps a Stiff Heart

Semaglutide is a GLP-1 receptor agonist — a synthetic version of the glucagon-like peptide-1 hormone that activates GLP-1 receptors throughout the body. In the context of HFpEF, three mechanisms appear most clinically relevant:

Reduction of Pericardial and Epicardial Fat

Weight loss from semaglutide preferentially reduces visceral and ectopic fat, including the deposits around the heart. Cardiac MRI substudy data from GLP-1 trials consistently show reductions in epicardial fat volume that correlate with improvements in diastolic function parameters. Less physical compression on the cardiac chambers directly reduces filling pressures.

Anti-Inflammatory Action

GLP-1 receptors are expressed on immune cells including macrophages. Semaglutide reduces circulating levels of CRP, IL-6, and TNF-alpha — the same cytokines that drive myocardial fibrosis in obesity-related HFpEF. This anti-inflammatory effect appears partly independent of weight loss, which explains why some cardiovascular benefits appear quickly and out of proportion to the degree of weight reduction.

Preload Reduction

By reducing total body weight and improving natriuretic peptide signaling, semaglutide lowers circulating blood volume and reduces venous return to the right heart. The result is a measurable reduction in left atrial pressure and pulmonary congestion — the direct cause of breathlessness in HFpEF. This preload reduction translates directly into the improved 6MWD seen in STEP-HFpEF.

Direct Cardiac Effects

GLP-1 receptors have been detected in human cardiac myocytes, though their physiological role remains under investigation. In animal models, GLP-1 receptor activation improves myocardial glucose utilization, reduces oxidative stress, and attenuates hypertrophy. Whether these direct cardiac effects are clinically meaningful in HFpEF is an active area of research.

5. HFrEF: Where Semaglutide Does NOT Belong (Yet)

The enthusiasm around STEP-HFpEF should not obscure a critical distinction: semaglutide has not demonstrated benefit — and may carry concerns — in heart failure with reduced ejection fraction.

Earlier clinical experience with liraglutide (another GLP-1 agonist) in the LIVE trial showed it did not improve cardiac function in HFrEF patients and was associated with a higher rate of serious adverse events in that population. While semaglutide is a different, more potent molecule, the HFrEF signal has not been positive.

Multiple ongoing trials are evaluating GLP-1 agonists specifically in HFrEF populations, but until those report out, the clinical consensus is clear: the HFpEF evidence is strong; the HFrEF picture is neutral-to-cautionary.

6. Evidence Summary: Major GLP-1 Trials in Cardiovascular Disease

7. The SELECT Trial: Cardiovascular Death and the Bigger Picture

While STEP-HFpEF answered the HFpEF symptom question, the SELECT trial answered the larger question: does semaglutide reduce the risk of dying from heart disease in high-risk patients without diabetes?

SELECT enrolled 17,604 adults who were overweight or obese (BMI ≥27), had established cardiovascular disease (prior MI, stroke, or peripheral artery disease), and did not have type 2 diabetes. They were randomized to semaglutide 2.4 mg weekly or placebo for a median follow-up of 33.3 months.

The result was a 20% relative risk reduction in major adverse cardiovascular events (the composite of cardiovascular death, non-fatal MI, or non-fatal stroke): hazard ratio 0.80 (95% CI 0.72–0.90, p<0.001). This was driven by reductions in non-fatal MI and non-fatal stroke — cardiovascular death alone did not reach significance.

Critically, the benefit appeared across subgroups and emerged despite the relatively short follow-up period. Weight loss alone is unlikely to explain a 20% MACE reduction in 33 months — the anti-inflammatory and direct vascular effects of semaglutide appear to be independent contributors.

8. Patient Eligibility: Who Should Talk to Their Doctor About GLP-1 for HFpEF?

Based on the STEP-HFpEF trial enrollment criteria and the emerging clinical consensus, the following profile describes patients most likely to benefit and to be considered appropriate candidates for discussion with a cardiologist:

Criteria Suggesting Potential Eligibility

• Confirmed HFpEF on echocardiography with ejection fraction ≥45–50%
• BMI ≥30 kg/m² (obese) — the effect was not tested in overweight HFpEF patients
• NYHA Class II, III, or IV heart failure symptoms (breathlessness, fatigue, reduced exercise tolerance)
• Elevated NT-proBNP (>300 pg/mL or >900 pg/mL in atrial fibrillation)
• Stable outpatient status (no HF hospitalization in prior 30–60 days)
• No contraindications to GLP-1 agonist therapy

Contraindications to Consider

• Personal or family history of medullary thyroid carcinoma or MEN2
• Severe kidney impairment (eGFR <20 mL/min/1.73m²)
• Active or recent pancreatitis
• Known hypersensitivity to semaglutide
• HFrEF (EF <40%) — this is a different disease; GLP-1 is not indicated

The Access Barrier: Insurance Coverage

Despite compelling trial data, insurance coverage for Wegovy in HFpEF patients remains inconsistent. The SELECT cardiovascular indication has improved coverage for patients with established CVD + obesity, but pure HFpEF without a prior MACE event may still require prior authorization. Work with your cardiologist's office to document the cardiac indication clearly in any authorization request.

Related Articles